American Journal of Kidney Diseases
Volume 52, Issue 3 , Pages 454-463 , September 2008

The Effect of Pentoxifylline on Proteinuria in Diabetic Kidney Disease: A Meta-analysis

  • Brendan B. McCormick, MD

      Affiliations

    • Division of Nephrology, Kidney Research Center, Ottawa Health Research Institute, Ottawa, Ontario, Canada
    • Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
    • Corresponding Author InformationAddress correspondence to Brendan B. McCormick, MD, Division of Nephrology, The Ottawa Hospital, Riverside Campus, 1967 Riverside Dr, Ottawa, Ontario, Canada K1H 7W9
    • ,
  • Amy Sydor, MD

      Affiliations

    • Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
    • ,
  • Ayub Akbari, MD

      Affiliations

    • Division of Nephrology, Kidney Research Center, Ottawa Health Research Institute, Ottawa, Ontario, Canada
    • Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
    • ,
  • Dean Fergusson, PhD

      Affiliations

    • Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
    • Clinical Epidemiology Program, Ottawa Health Research Institute, Ottawa, Ontario, Canada
    • ,
  • Steve Doucette, MSc

      Affiliations

    • Clinical Epidemiology Program, Ottawa Health Research Institute, Ottawa, Ontario, Canada
    • ,
  • Greg Knoll, MD, MSc

      Affiliations

    • Division of Nephrology, Kidney Research Center, Ottawa Health Research Institute, Ottawa, Ontario, Canada
    • Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
    • Clinical Epidemiology Program, Ottawa Health Research Institute, Ottawa, Ontario, Canada

Received 7 September 2007 ,Accepted 2 January 2008.

References 

  1. Ehrly AM. Improvement of the flow properties of blood: A new therapeutical approach in occlusive arterial disease. Angiology. 1976;27:188–196
  2. De Sanctis MI, Cesarone MR, Belcaro G, et al. Treatment of intermittent claudication with pentoxifylline: A 12-month, randomized trial—Walking distance and microcirculation. Angiology. 2002;53(suppl 1):S7–S12
  3. Ward A, Clissold SP. Pentoxifylline (A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy). Drugs. 1987;34:50–97
  4. Blagosklonnaia T, Mamedov R, Kozlov VV, et al. Effect of Trental on indices of kidney function in diabetes mellitus. Probl Endokrinol (Mosk). 1982;28:3–8
  5. Sinzinger H. Pentoxifylline enhances formation of prostacyclin from rat vascular and renal tissue. Prostaglandins Leukot Med. 1983;12:217–226
  6. Navarro JF, Mora C, Rivero A, et al. Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: Effects of pentoxifylline administration. Am J Kidney Dis. 1999;33:458–463
  7. Navarro JF, Mora C, Muros M, Garcia J. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: A short-term, randomized, controlled trial. J Am Soc Nephrol. 2005;16:2119–2126
  8. Cooper A, Mikhail A, Lethbridge MW, et al. Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. J Am Soc Nephrol. 2004;15:1877–1882
  9. Chen YM, Lin SL, Chiang WC, et al. Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases. Kidney Int. 2006;69:1410–1415
  10. Yagmurlu A, Boleken ME, Ertoy D, et al. Preventive effect of pentoxifylline on renal scarring in rat model of pyelonephritis. Urology. 2003;61:1037–1041
  11. Lin SL, Chen YM, Chien CT, et al. Pentoxifylline attenuated the renal disease progression in rats with remnant kidney. J Am Soc Nephrol. 2002;13:2916–2929
  12. Lin SL, Chen RH, Chen YM, et al. Pentoxifylline attenuates tubulointerstitial fibrosis by blocking smad 3/4-activated transcription and profibrogenic effects of connective tissue growth factor. J Am Soc Nephrol. 2005;16:2702–2713
  13. Rossing P. Diabetic nephropathy: Worldwide epidemic and effects of current treatment on natural history. Curr Diab Rep. 2006;6:479–483
  14. Jaddad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Control Clin Trials. 1996;17:1–12
  15. Solerte SB, Fioravanti M, Patti AL, et al. Pentoxifylline, total urinary protein excretion rate and arterial blood pressure in long-term insulin-dependent diabetic patients with overt nephropathy. Acta Diabetol Lat. 1987;24:229–239
  16. Guerrero-Romero F, Rodriguez-Moran M, Paniagua-Sierra JR, et al. Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients. Clin Nephrol. 1995;43:116–121
  17. Garg SK, Chase HP, Jackson WE, et al. Renal and retinal changes after treatment with ramipril and pentoxifylline in subjects with IDDM. Ann Opthalmol. 1998;30:33–37
  18. Navarro JF, Mora C, Garcia J, et al. Effects of pentoxifylline on the haematologic status in anaemic patients with advanced renal failure. Scand J Urol Nephrol. 1999;33:121–125
  19. Pantoja R, Woronik V, Barros R. Effects of pentoxifylline in diabetic nephropathy. Nephrol Dial Transplant. 2003;18(suppl 4):S104A;(abstr)
  20. Harmankaya O, Seber S, Yilmaz M. Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients. Re Fail. 2003;25:465–470
  21. Navarro JF, Mora C, Muros M, et al. Effects of pentoxifylline administration on urinary N-acetyl-β-glucosaminidase excretion in type 2 diabetic patients: A short-term, prospective, randomized study. Am J Kidney Dis. 2003;42:264–270
  22. Aminorroaya A, Janghorbani M, Rezvanian H, et al. Comparison of the effects of pentoxifylline and captopril on proteinuria in patients with type 2 diabetes mellitus. Nephron Clin Pract. 2005;99:73–77
  23. Rodriguez-Moran M, Guerro-Romero F. Pentoxifylline is as effective as captopril in the reduction of microalbuminuria in non-hypertensive type 2 diabetic patients—A randomized, equivalent trial. Clin Nephrol. 2005;64:91–97
  24. Eijkelkamp WB, Zhang Z, Remuzzi G, et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: Post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol. 2007;18:1540–1546
  25. Olsen MH, Wachtell K, Ibsen H, et al. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: The LIFE Study. J Hypertens. 2006;24:775–781
  26. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease (The Modification of Diet in Renal Disease Study). Ann Intern Med. 1995;15:754–762
  27. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860
  28. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869
  29. Dalla Vestra M, Mussap M, Gallina P, et al. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol. 2005;16(suppl 1):S78–S82
  30. McCarthy ET, Sharma R, Sharma M, et al. TNF-alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide. J Am Soc Nephrol. 1998;9:433–438
  31. Zandi-Nejad K, Eddy AA, Glassock RJ, Brenner BM. Why is proteinuria an ominous biomarker of progressive kidney disease?. Kidney Int Suppl. 2004;92:S76–S89
  32. Navarro JF, Milena FJ, Mora C, et al. Tumor necrosis factor-alpha gene expression in diabetic nephropathy: Relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition. Kidney Int Suppl. 2005;99:S98–S102
  33. Han SY, Kim CH, Kim HS, et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol. 2006;17:1362–1372
  34. Gore-Hyer E, Sheqoque D, Markiewicz M, et al. TGF-beta and CTGF have overlapping and distinct fibrogenic effects on human renal cells. Am J Physiol Renal Physiol. 2002;283:F707–F716
  35. Paap CM, Simpson KS, Horton MW, et al. Multiple-dose pharmacokinetics of pentoxifylline and its metabolites during renal insufficiency. Ann Pharmacother. 1996;30:724–729
  36. http://www.cochrane.org/resources/handbook/hbook.htm. Accessed November 30, 2007

 Originally published online as doi:10.1053/j.ajkd.2008.01.025 on April 21, 2008.

PII: S0272-6386(08)00478-2

doi: 10.1053/j.ajkd.2008.01.025

American Journal of Kidney Diseases
Volume 52, Issue 3 , Pages 454-463 , September 2008

Article Tools

* Image Usage & Resolution